Jacob sands
@sands_jacob
Followers
1K
Following
2K
Media
55
Statuses
676
Thoracic oncologist, Dana-Farber Cancer Institute. Assistant Professor, Harvard Medical School
Boston, MA
Joined November 2014
🚨 Excited to share our 2 new studies published today in @TheLancetOncol — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. @OncoAlert @IASLC #LCSM. /W✨@DiFedericoMD✨
6
58
177
In an interview with @boston25, @danafarber’s @sands_jacob talks about new lung cancer treatment breakthroughs. @DFarberThoracic Watch here:
boston25news.com
0
1
4
Immunotherapy Advances Transform Small Cell Lung Cancer Care @sands_jacob @DanaFarberNews @DanaFarber @harvardmed @IASLC #Oncology #WCLC25
curetoday.com
Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures.
0
1
5
Tune in to learn the potential benefits of innovative ADCs in #SCLC. Get up to date on the evolving guidelines and clinical evidence supporting the emerging therapeutics in this must-see #PeerView #MedEd activity with Jacob Sands, MD (@sands_jacob) https://t.co/HDedchEnyg
#LCSM
0
2
6
Thank you @DrewMoghanaki for the post. I look forward to the Rescue Lung Society each year, and this is lined up to be another amazing one. October 23-25 in Boston (remote attend option too). So many world leaders in person! See agenda & register at https://t.co/XN4JEcy2RH
#LCSM
rescuelung.org
Rescue Lung Society 2025 Conference, RLS 2025, RLS Conference, RLS Boston, RLRL Conference
🫁 Watch this brief video to learn how Ray O was blown away by last year's Rescue Lung conference. If you listen carefully, you'll recognize the interviewer (hint: it's @sands_jacob). This unique conference brings together the strongest thought leaders in lung cancer screening
1
2
9
Thank you to @ReachMD for the opportunity to discuss PD-L1 negative disease and long term results of CTLA/PD1 dual immunotherapy with my esteemed colleague Dr Jacob Sands @sands_jacob. https://t.co/D9YsZjqPvR
reachmd.com
The CheckMate 9LA trial evaluated nivolumab plus ipilimumab with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (mNSCLC) in patients with low PD-L1 expression. The...
1
3
12
DatoDXd is now approved for previously treated mEGFR NSCLC based off #TROPIONLung01 & 05! We had a chance to 🗣️ this trial, findings, AEs and sequencing w/ @sands_jacob Full 🗣️: ⭐️ https://t.co/kTFnHPYevE ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm
1
16
46
Be sure to attend #DCLung25 - Saturday, October 4th in Washington DC: a one-day @IASLC endorsed lung cancer conference with experts like Dr. Jacob Sands @sands_jacob, who will lead our discussion on small cell lung cancer #SCLC. Register today! https://t.co/OJz1a1lAHb
2
4
21
🚨 New! US expert Delphi consensus on the prevention and management of #stomatitis in patients treated with #DatopotamabDeruxtecan 🔓 https://t.co/rG6o7vByPS
@hoperugo @dradityabardia @ErikaHamilton9 @jhaveri_komal @BCJoyceO @sands_jacob @stolaney1 #OralMucositis #DatoDXd
0
14
20
Looking at the latest data from ASCO for SCLC, why does the OS benefit seem stronger than PFS? Is there a real plateau in the data? And how should we interpret non-significant subgroups? Watch the answers from @peters_solange, @g_mountzios & @sands_jacob and the full recording 📊
0
9
26
CAR-T in #SCLC ! Dr. @sands_jacob of @DFarberThoracic shows early signals in SCLC with LB2102. Thanks to our #ImmuneEffectorCell solid tumor group for their help with this study! #DAVALung #lcsm #lcam #HawaiiLung25 @SclcSMASHERS
0
5
22
FDA has granted accelerated approval to datopotamab deruxtecan (Dato‑DXd) for EGFR‑mutated NSCLC, marking a promising new option in lung cancer care. Kudos to Dr. @sands_jacob and team on this milestone. https://t.co/AWTDn6cMBR
#LungCancer #OncologyNews
ascopost.com
The FDA approved the agent for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.
1
2
11
Two checkpoint inhibitors in #SCLC got approved in Europe based on data from Asian populations only. Does it matter and which ICI should we use? See @g_mountzios sharing his take. Watch the full roundtable with more highlights together with @peters_solange & @sands_jacob now ⬇️
1
10
30
So much fun recording this educational video with @sands_jacob @DanaFarber and @elaineshum @nyulangone on Evaluating #DatoDXd for #EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis https://t.co/bA2wjXkN27 via @ReachMD @EGFRResisters
2
7
40
LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC @sands_jacob @DanaFarber @ASCO #ASCO25 #lcsm #oncology
onclive.com
The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.
1
3
4
🚨 TODAY Don't miss today's roundtable on the latest progress in treating small cell lung cancer with renowned experts, @peters_solange, @g_mountzios and @sands_jacob! #ASCO25 #LCSM ⏰ 17ᵗʰ June at 5PM CEST Tune in for free ⬇️
0
7
14
Dr. @ChiFuJeffYang @MGHSurgery & @HarvardMed shares key updates on surgery for small cell lung cancer & the impact of screening. From new guidelines to national outreach via @AmLungCSI, he's helping shape the future of SCLC care. Watch & subscribe -> https://t.co/perXjpXeNO
1
6
16
There’s a lot to discuss about small cell lung cancer. Looking forward to this discussion soon with exceptional colleagues. The field is moving forward! #LCSM
How do leading thoracic oncologists address the challenges of #SCLC in both limited- and extensive-stage disease? Join @sands_jacob together with @peters_solange and @g_mountzios exploring the latest clinical developments in #SCLC ⏰ 17ᵗʰ June at 5PM CEST ✅ CME-certified ⬇️
1
3
9